NIH study finds Cediranib benefits patients with ASPS
An experimental drug, cediranib, may benefit alveolar soft part sarcoma (ASPS) patients, according a recent clinical trial. The trial, carried out by scientists at the National Cancer Institute (NCI), part of the National Institutes of Health, showed that tumors shrank in more than 50 percent of ASPS patients who were treated with cediranib. These findings […]